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There is a strong association between chronic kidney disease
(CKD) and an elevated blood pressure (BP) whereby each
can cause or aggravate the other. BP control is fundamental
to the care of patients with CKD and is relevant at all stages
of CKD regardless of the underlying cause. Clinical practice
guidelines (CPGs) have been published on this topic by
many authoritative bodies over the past decade, the most
comprehensive being the National Kidney Foundation’s
(NKF) Kidney Disease Outcomes Quality Initiative (KDOQI)
Clinical Practice Guidelines on Hypertension and Antihyper-
tensive Agents in Chronic Kidney Disease, which was based
on evidence collected up to 2001 (http://www.kidney.org/
professionals/KDOQI/guidelines_bp/index.htm).1 The Kid-
ney Disease: Improving Global Outcomes (KDIGO) Board
believed that it would be clinically useful to update this CPG
to incorporate the evidence gathered since then. KDIGO
therefore commissioned an evidence review to include the
recent literature and assembled a Work Group with the
mandate of writing an updated guideline relevant to an
international audience. This KDIGO Guideline, entitled
‘‘Management of Blood Pressure in Chronic Kidney Disease,’’
is the result of these efforts.
Scope of this guideline
This Guideline has been developed to provide advice on the
management of BP in patients with non–dialysis-dependent
CKD (CKD ND) (see Reference Keys).
BP. We have avoided using the term ‘hypertension’ in
our title because this implies that there is a BP value
above or below which morbidity or mortality changes in a
stepwise fashion, hence suggesting that it is possible to set a
universal BP target. In reality, it proved difficult to define
precise targets appropriate for all CKD subpopulations,
consistent with the notion that the ‘ideal’ BP may
differ between patients, once other factors are considered.
These factors include specific features of CKD such as the
severity of albuminuria or proteinuria, the presence of
other risk factors for cardiovascular disease (CVD) and co-
morbidities. Another reason for our choice of terminology is
that agents introduced primarily to treat high BP may
have actions that may not be directly linked to BP-lowering
(e.g., the anti-albuminuric effects of angiotensin-converting
enzyme inhibitors [ACE-Is] and angiotensin-receptor
blockers [ARBs]).
Definition of CKD. The Work Group defined CKD
according to the standard KDOQI classification system2 as
endorsed by KDIGO.3
Populations of interest. The populations covered in this
guideline are:
K Adults with CKD ND without diabetes mellitus
K Adults with CKD ND with diabetes mellitus
K Adults with CKD ND who have received a kidney
transplant (CKD T)
K Children with CKD ND
K Elderly with CKD ND
The scope of this guideline did not include BP manage-
ment in patients with dialysis-dependent CKD 5 (CKD 5D)
since this has been the topic of a recent KDIGO consensus
conference4 and has been covered by two recent systematic
reviews.5,6 There are other groups of patients with CKD for
whom specific recommendations might be welcome, but who
are not represented in sufficient numbers in randomized
controlled trials (RCTs) to constitute a sufficiently robust
evidence base. The evidence review team (ERT) was asked to
present the evidence separately for adults with CKD and
diabetes, since these individuals constitute the single largest
subgroup of CKD patients in the world.
The separation of the evidence base according to diabetes
status meant that there were two separate datasets for the
Work Group to review. Although the two sets of recommen-
dations had much in common, the Work Group decided that
they differed sufficiently in detail to warrant two separate
chapters. Adults who received a kidney transplant, children,
and the elderly were also thought to deserve dedicated
chapters, although the evidence base for each of these
subpopulations is rather small.
The Work Group was unable to identify sufficient
evidence to make recommendations according to severity
(stage) of CKD, although common sense dictates that
pharmacological management should differ at least between
mild CKD (patients with normal glomerular filtration rate
[GFR]) and advanced CKD (patients with low GFR).
However, the Work Group did consider the modification
of drug dosages and risks related to the various classes of
BP-lowering agents in the context of CKD in Chapter 2.
Clearly there are many other populations that could have
been considered. CKD patients with glomerulonephritis are
the subject of a recent KDIGO Guideline,7 so they were not
considered separately here. Although management of BP in the
pregnant CKD patient is an important issue, there is insuf-
ficient evidence in this subgroup to allow recommendations
to be made.8 Furthermore, the Work Group did not
consider the management of BP in patients with acute
kidney injury.
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Interventions. Interventions primarily aiming at modify-
ing BP include advice on lifestyle and administration of
pharmacological agents that reduce BP. The efficacies of both
strategies have been widely studied in the general population
with high BP. The pharmacology of anti-hypertensive agents
was detailed in the 2004 KDOQI guideline.1
Of the available RCTs that met our inclusion criteria, most
involved agents interfering with the renin-angiotensin-
aldosterone system (RAAS). Accordingly, these agents may
be over-represented in this Guideline, and if so, it is because
of the availability of the evidence rather than a deliberate
focus by the Work Group.
Evidence for interventions
Because CKD is common and BP levels are often elevated
in CKD populations, the management of BP in CKD patients
could have an enormous global impact. Given that the focus
of the Guideline is on management and the comparative
effectiveness of various interventions, the preferred and
most robust evidence is derived from large-scale RCTs
which assessed hard clinical outcomes. The ERT was
asked to include RCTs with a minimum of 50 patients in
each arm and interventions included pharmacological agents
(alone or in combination), lifestyle modifications, and
trials assessing various levels of BP control. Outcomes
of interest were mortality, cardiovascular events and changes
in kidney function including urine albumin or protein
excretion.
Reduction in BP, particularly when achieved using agents
that interfere with the RAAS, can lead to acute reductions in
kidney function and albuminuria; thus the minimal duration
of follow-up in RCTs required for their inclusion in the
evidence review was set at 1 year for kidney function, cardi-
ovascular outcomes, and mortality and 3 months for urine
albumin or protein levels. Because there were so few trials
assessing lifestyle modifications, BP reduction was included
as an outcome, with the minimum follow-up period set
at 6 weeks.
The approach to the evidence review is described in detail
in Methods for Guideline Development. The ERT conducted a
systematic review of RCTs involving individuals with CKD.
This was supplemented with published systematic reviews
and meta-analyses (which often included smaller RCTs).
Work Group members further supplemented this yield with
selected RCTs that included individuals at increased risk of
CVD but who were not specifically chosen on the basis of
having CKD. The Work Group also helped identify RCTs that
included CKD subgroups. To a lesser extent, the Work Group
made reference to observational evidence from large popula-
tion studies where evidence from RCTs was perceived to be
insufficient.
Not all questions of interest have been the subject of RCTs;
some issues do not lend themselves to be studied in this
manner. To facilitate further discussion on major issues
relevant to management of BP in CKD patients (for which
there is some evidence but ongoing controversy remains), the
Work Group included a chapter on Future Directions and
Controversies (Chapter 8). For other issues widely accepted in
practice, but not supported by evidence from RCTs, the Work
Group wrote ungraded recommendations reflecting the
consensus of its members. These ungraded statements are
explained in detail in the accompanying narrative.
The Work Group did not wish to provide advice on
specific treatment questions for which there was no
supporting evidence. By highlighting these gaps in knowl-
edge, we aim to promote further research.
During the preparation of this Guideline, the Work Group
was aware that other international organizations were writing
new or updating old guidelines that were potentially relevant
to the management of BP in CKD patients. The Work Group
kept in contact with these other organizations and sought to
achieve consistency with their recommendations as much as
possible.
Measurement of BP
The Work Group recognized that many reviews on the
methodology of BP measurement have been published9,10 and
that this topic was covered in detail in the 2004 KDOQI
Guideline.1 Previous publications have highlighted incon-
sistencies between conventional office (or clinic) BP measure-
ments and other methods, such as self-measurement of BP at
home or ambulatory blood pressure monitoring (ABPM).11–13
Many recommendations regarding when and how to use
ABPM in hypertensive patients not known to have CKD have
also been published. Although few studies have assessed the
value of ABPM CKD patients, the small, short-term studies
that do exist reflect the inconsistency between office BP
measurements and other BP measurements and also suggest
that ABPM gives a better indication of overall BP and kidney
prognosis than office BP measurements.11–13 Despite this, to
date there has only been one large RCT of BP control in CKD
patients (all of whom were children) in which ABPM was
used as the method for BP assessment.14 We therefore cannot
provide evidence-based recommendations regarding the use
of ABPM to evaluate BP in CKD patients but existing
evidence is reviewed in Chapter 8.
Since office BP measurements are used in almost all RCTs
of interventions that modify BP in CKD, this Guideline can
only make recommendations about BP assessed by this
method. Because office readings are known to vary from day
to day, management decisions should be based on repeated
measurements,15 as emphasized in this guideline by the use of
the term ‘consistently’ (e.g., Recommendation 4.1 y
maintain a BP that is consistently r140 mm Hg systolic y).
The term is used simply to imply that the BP has been
measured more than once and that there was meaningful
agreement between the measurements.
The Work Group also discussed whether to consider pulse
pressure and/or pulse wave velocity, measures of arterial
compliance that may provide important prognostic informa-
tion in CKD patients. However, there is a paucity of data
from RCTs showing that any particular intervention reliably
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alters these measures and subsequently influences mortality
or morbidity. Thus the Work Group was not able to make
any evidence-based recommendations relating to these
measurements. However, these issues are of interest for the
future of BP assessment in CKD patients and are discussed in
further detail in Chapter 8.
Albuminuria and proteinuria
Some BP-lowering agents are particular effective at reducing
albuminuria or proteinuria, suggesting that BP management
should differ depending on the amount of albumin or
protein in the urine.16–19 Accordingly, as in the KDOQI 2004
Guidelines and the majority of other CPGs addressing BP
control in patients with CKD or diabetes, the Work Group
has attempted to stratify treatment effects according to
urinary albumin excretion. Based on a recent KDIGO
Controversies Conference and data from the CKD Prognosis
Consortium, the Work Group used three categories (levels)
of albuminuria.20 Wherever possible, the Work Group
modified its recommendations to fit these categories,
although since not all RCTs use this classification system,
consistency was not achievable. The three categories of
urinary albumin excretion are as follows: 4300 mg per 24 h
(or ‘macroalbuminuria’), 30 to 300 mg per 24 h (or ‘micro-
albuminuria’), and o30 mg per 24 h (Table 1). When other
measures (such as assessment of proteinuria, ratios of urinary
albumin or urinary protein to urine creatinine, or protein
reagent strip readings) were used in RCTs, these measures
were translated to albumin excretion rates (AERs) per 24 h,
recognizing that these converted values are approximations at
best. Recommendations and suggestions for interventions
based on albumin levels expressed in milligrams per 24 h can
also be converted (Table 1).
BP thresholds and targets
Perhaps the most important questions for health care
professionals are first, at what BP level should BP-lowering
strategies be introduced in CKD patients (i.e., what is the BP
treatment threshold?), and second, what BP levels should be
aimed for (i.e., what is the BP treatment target?). Although
the evidence base for the BP treatment threshold differs from
the evidence base for the BP target, we could not find a
robust justification to recommend different BP levels for
these two parameters. Doing so might also lead to confusion,
since we would be recommending two different BP levels
possibly with two evidence ratings and would not be able to
provide coherent advice for managing patients between the
recommended threshold and target BPs.
Studies that have not specifically targeted CKD patients
demonstrate that BP is a continuous risk factor for CVD
outcomes.21 BP targets could differ depending on the
presence of other CVD risk factors in each patient. This
approach contrasts with the ‘one size fits all’ philosophy that
has previously been endorsed. There are far less data in CKD
patients to inform the best approach. In RCTs involving CKD
patients who are randomized to different BP targets, the
achieved differences between groups are usually less than the
targeted differences. Intention-to-treat analyses allow con-
clusions to be drawn based on target BP levels rather than
achieved BP levels. The Work Group generally followed this
convention and based recommendations on target levels BP
levels rather than those achieved in the RCTs. It also
considered the evidence derived from RCTs in which patients
were not randomized to BP targets but achieved BPs were
reported. The logic for using target BP levels in RCTs rather
than the achieved BP levels observed as the basis for setting
guideline targets has been questioned;22 this concern is one
reason for our conservative approach to BP target setting in
this Guideline.
Outcomes
The major outcomes relevant to BP control in CKD patients
are kidney disease progression and cardiovascular events
(including stroke).
Kidney outcomes. Although it is possible for a diagnosis
of CKD to be made in an individual with a normal GFR and
AER and even a normal BP (for example on the basis of an
imaging study, as in early adult polycystic kidney disease),
most patients recruited into RCTs addressing BP and its
management in CKD have a reduced GFR or persistently
elevated albumin excretion. Entry criteria for RCTs involving
Table 1 | Relationship among categories for albuminuria and
proteinuriaa
Categories
Measure
Normal to mildly
increased
Moderately
increased
Severely
increased
AER (mg/24 h) o30 30–300 4300
PER (mg/24 h) o150 150–500 4500
ACR
(mg/mmol) o3 3–30 430
(mg/g) o30 30–300 4300
PCR
(mg/mmol) o15 15–50 450
(mg/g) o150 150–500 4500
Protein reagent
strip
Negative to trace Trace to + + or greater
ACR, albumin/creatinine ratio; AER, albumin excretion rate; PCR, protein/creatinine
ratio, PER, protein excretion rate.
Albuminuria and proteinuria can be measured using excretion rates in timed urine
collections, ratio of concentrations to creatinine concentration in spot urine
samples, and using reagent strips in spot urine samples. Relationships among
measurement methods within a category are not exact.
The relationships between AER and ACR and between PER and PCR are based on
the assumption that average creatinine excretion rate is approximately 1.0 g/24 h
or 10mmol/24 h. The conversions are rounded for pragmatic reasons. (For an
exact conversion from mg/g of creatinine to mg/mmol of creatinine, multiply
by 0.113.) Creatinine excretion varies with age, sex, race and diet; therefore
the relationship among these categories is approximate only. ACR o10mg/g
(o1mg/mmol) is considered normal; ACR 10–29mg/g (1.0–2.9mg/mmol) is
considered ‘high normal.’
The relationship between urine reagent strip results and other measures depends
on urine concentration.
aTentatively adopted by KDIGO CKD Work Group.
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CKD patients are usually based on these parameters, changes
in which may form the basis for kidney end points.
Kidney function. Changes in kidney function are impor-
tant outcomes in clinical trials assessing the effects of various
BP-management regimens in CKD patients. Although the
most important events are the requirement for renal
replacement therapy or death due to kidney failure, many
studies have used surrogates such as changes in GFR or the
percentage of patients in whom the serum creatinine (SCr)
level doubles. Such numerical end points may be particularly
relevant in trials that include patients with early-stage CKD,
among whom kidney failure and death are uncommon
events. One problem with the assessment of such surrogates
is that the therapeutic agent used to modify BP may also
directly alter kidney function. For example, ACE-Is are
known to reduce GFR through a vasodilator effect on the
efferent arteriole. This effect may be beneficial in the early
stages of CKD when a reduced intra-glomerular pressure is
protective, but might be detrimental at a later stage when
kidney function is severely compromised and dialysis may be
imminent, at which time GFR may increase if ACE-Is are
withdrawn.23 Thus, a drug may modify GFR via a mechanism
that does not directly involve changes in systemic BP and the
impact of this effect on the patient may vary according to
CKD stage. The Work Group bore such considerations in
mind when assessing the evidence and viewed consistency in
the change of GFR outcomes across various CKD stages as a
strong indicator of the benefits of a particular agent on
kidney function.
Albuminuria. The level of albuminuria in CKD predicts
not only the prognosis with respect to kidney function but
also morbidity and mortality from CVD events including
stroke.16–19 Urinary albumin excretion is influenced by BP
and by many of the agents used to reduce BP, particularly
ACE-Is and ARBs.
The concept of using albuminuria as a surrogate marker
for CKD progression and CVD outcomes is widely accepted,
with the reduction of urine albumin levels often being
regarded as a target for therapy. This would mean that
treatment would be escalated to reduce albuminuria to a
preferred level, regardless of BP. Treating to an albumin target
usually involves an escalation of RAAS blockade, which can
be achieved by restricting dietary salt intake, increasing doses
of an ACE-I or an ARB, combining the two classes of
medication, or by adding a thiazide diuretic, an aldosterone-
receptor blocker or a direct renin inhibitor (DRI).
While a strong case has been made for targeting a
reduction of albuminuria, particularly with agents that
interfere with the RAAS, there have been no large studies
in CKD patients reporting long term differences in GFR or
CVD outcomes where reduction in urinary albumin levels
(regardless of BP) was the primary objective. There is also
uncertainty as to whether the dose of a particular agent that
is required to achieve BP control is necessarily the same as the
dose required for albuminuria reduction.24 The Work Group
thus decided that it was premature to recommend an
albuminuria reduction target strategy for all cases of CKD
but felt this deserved further discussion in Chapter 8.
Cardiovascular outcomes. Recognition that premature
CVD is a major cause of death in CKD has led to CVD
risk management becoming a recognized component of the
care of the CKD patient. In planning appropriate interven-
tions, one strategy is simply to extrapolate data from CVD
outcomes trials in the general population. This approach has
been challenged because the benefits of interventions
predicted in observational studies25 are not always observed
in RCTs involving CKD patients.26,27 In CKD-ND patients,28
unlike CKD patients on dialysis (CKD 5D),29 a higher BP is
generally associated with a higher CVD risk, making BP-
lowering an attractive goal in an effort to reduce cardiovas-
cular morbidity and mortality.
Although no RCTs assessing BP lowering agents have been
specifically designed or powered to assess cardiovascular
event rates as the primary outcome in any group of CKD
patients, several studies assessing cardiovascular outcomes
have included CKD patients and this information was
considered in making the recommendations.
Intended Users of this Guideline
This Guideline is primarily aimed at health care professionals
caring for individuals with CKD, including nephrologists,
nurses, and pharmacists, as well as at physicians involved in
the care of patients with diabetes and primary care providers.
The Guideline is not aimed at health care administrators,
policy makers, or regulators, although the explanatory text
might be of value to these groups and assist in enhancing
implementation and adherence to BP-lowering strategies.
The Guideline is also not designed to be used in the
development of clinical performance measures. Some of the
difficulties in implementation and in auditing BP target
achievement are discussed in Chapter 8.
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